NCT04726332View on ClinicalTrials.gov

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

PHASE1TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

May 2, 2024

Study Completion Date

May 2, 2024

Conditions
Neoplasm MalignantEpithelial Ovarian CancerTriple Negative Breast CancerHormone Receptor Positive Breast CarcinomaMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

XL102

oral doses of XL102

DRUG

Fulvestrant

fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.

DRUG

Abiraterone

abiraterone 1000 mg administered orally once daily.

DRUG

Prednisone

prednisone 5 mg administered orally twice daily.

Trial Locations (5)

30322

Exelixis Clinical Site #4, Atlanta

75230

Exelixis Clinical Site #2, Dallas

77030

Exelixis Clinical Site #5, Houston

78229

Exelixis Clinical Site #1, San Antonio

02215

Exelixis Clinical Site #3, Boston

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY

NCT04726332 - Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Biotech Hunter | Biotech Hunter